Alyria Teixeira Dias1, Sandra Bertelli Ribeiro de Castro2, Caio César de Souza Alves3, Marcilene Gomes Evangelista1, Luan Cristian da Silva1, Daniele Ribeiro de Lima Reis4, Marco Antonio Machado4, Maria Aparecida Juliano5, Ana Paula Ferreira6. 1. IMUNOCET, Department of Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, 36036-900, Brazil. 2. Department of Pharmacy, Federal University of Juiz de Fora, Governador Valadares, Brazil. 3. Faculty of Medicine, Federal University of the Valleys of Jequitinhonha and Mucuri, Teófilo Otoni, Brazil. 4. Empresa Brasileira de Pesquisa Agropecuária, Juiz de Fora, Brazil. 5. Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil. 6. IMUNOCET, Department of Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, 36036-900, Brazil. ana.paula@ufjf.edu.br.
Abstract
OBJECTIVE AND DESIGN: The present work investigates the modulation of experimental autoimmune encephalomyelitis (EAE) using genistein before the EAE induction. MATERIAL: Female C57BL/6 mice (n = 96 mice/experiment), 4-6 weeks old, were used to induce the EAE. The mice were divided into three experimental groups: non-immunized group, immunized group (EAE), and immunized and treated with genistein group (Genistein). TREATMENT: Genistein was used at a dose of 200 mg/kg s.c. and were initiated 2 days before the immunization and continued daily until day 6 postimmunization. METHODS: Animals were monitored daily for clinical signs of EAE up to day 21. Inflammatory infiltration, demyelination, Toll-like receptor (TLR) expression, cytokines and transcription factors were analyzed in spinal cords. RESULTS: The present study demonstrates, for the first time, the genistein ability to modulate the factors involved in the innate immune response in the early stages of EAE. The genistein therapy delayed the onset of the disease, with reduced inflammatory infiltration and demyelination. In addition, the expression of TLR3, TLR9 and IFN-β were increased in genistein group, with reduction in the factors of TH1 and Th17 cells. CONCLUSION: These findings shed light on the potential of genistein as a prophylactic strategy for multiple sclerosis (MS) prevention.
OBJECTIVE AND DESIGN: The present work investigates the modulation of experimental autoimmune encephalomyelitis (EAE) using genistein before the EAE induction. MATERIAL: Female C57BL/6 mice (n = 96 mice/experiment), 4-6 weeks old, were used to induce the EAE. The mice were divided into three experimental groups: non-immunized group, immunized group (EAE), and immunized and treated with genistein group (Genistein). TREATMENT: Genistein was used at a dose of 200 mg/kg s.c. and were initiated 2 days before the immunization and continued daily until day 6 postimmunization. METHODS: Animals were monitored daily for clinical signs of EAE up to day 21. Inflammatory infiltration, demyelination, Toll-like receptor (TLR) expression, cytokines and transcription factors were analyzed in spinal cords. RESULTS: The present study demonstrates, for the first time, the genistein ability to modulate the factors involved in the innate immune response in the early stages of EAE. The genistein therapy delayed the onset of the disease, with reduced inflammatory infiltration and demyelination. In addition, the expression of TLR3, TLR9 and IFN-β were increased in genistein group, with reduction in the factors of TH1 and Th17 cells. CONCLUSION: These findings shed light on the potential of genistein as a prophylactic strategy for multiple sclerosis (MS) prevention.
Authors: Alyria Teixeira Dias; Sandra Bertelli Ribeiro De Castro; Caio César De Souza Alves; Felipe Pereira Mesquita; Nathália Stela Visoná De Figueiredo; Marcilene Gomes Evangelista; Maria Christina Marques Nogueira Castañon; Maria Aparecida Juliano; Ana Paula Ferreira Journal: Cell Immunol Date: 2015-01-07 Impact factor: 4.868
Authors: Aditi Kanhere; Arnulf Hertweck; Urvashi Bhatia; M Refik Gökmen; Esperanza Perucha; Ian Jackson; Graham M Lord; Richard G Jenner Journal: Nat Commun Date: 2012 Impact factor: 14.919
Authors: Luisa F Duarte; Mónica A Farías; Diana M Álvarez; Susan M Bueno; Claudia A Riedel; Pablo A González Journal: Front Cell Neurosci Date: 2019-02-26 Impact factor: 5.505